HomeCompareVCF vs MRK

VCF vs MRK: Dividend Comparison 2026

VCF yields 155.52% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VCF wins by $347.2K in total portfolio value
10 years
VCF
VCF
● Live price
155.52%
Share price
$13.82
Annual div
$21.49
5Y div CAGR
-22.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$405.0K
Annual income
$23,001.53
Full VCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — VCF vs MRK

📍 VCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VCF
Annual income on $10K today (after 15% tax)
$13,219.15/yr
After 10yr DRIP, annual income (after tax)
$19,551.30/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, VCF beats the other by $10,954.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VCF + MRK for your $10,000?

VCF: 50%MRK: 50%
100% MRK50/50100% VCF
Portfolio after 10yr
$231.3K
Annual income
$16,557.65/yr
Blended yield
7.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VCF
No analyst data
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VCF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVCFMRK
Forward yield155.52%2.81%
Annual dividend / share$21.49$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-22.7%32.7%
Portfolio after 10y$405.0K$57.7K
Annual income after 10y$23,001.53$10,113.78
Total dividends collected$286.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VCF vs MRK ($10,000, DRIP)

YearVCF PortfolioVCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$22,722$12,021.65$11,213$373.04+$11.5KVCF
2$44,045$19,733.29$12,667$512.06+$31.4KVCF
3$74,763$27,634.81$14,439$708.14+$60.3KVCF
4$113,884$33,887.57$16,640$988.16+$97.2KVCF
5$159,148$37,291.62$19,432$1,394.07+$139.7KVCF
6$207,936$37,648.15$23,057$1,992.90+$184.9KVCF
7$258,028$35,536.04$27,889$2,894.79+$230.1KVCF
8$307,947$31,856.71$34,518$4,286.29+$273.4KVCF
9$356,970$27,466.63$43,912$6,494.35+$313.1KVCF
10$404,959$23,001.53$57,714$10,113.78+$347.2KVCF

VCF vs MRK: Complete Analysis 2026

VCFStock

Delaware Investments Colorado Municipal Income Fund, Inc. is a closed-ended fixed income mutual fund launched by Delaware Management Holdings, Inc. It is managed by Delaware Management Business Trust. The fund invests in the fixed income markets of the United States. It primarily invests in un-insured, investment grade, tax-exempt Colorado municipal obligations, including airport revenue bonds, city general obligation bonds, continuing care/retirement revenue bonds, convention center/auditorium/hotel revenue bonds, dedicated tax and fees revenue bonds, higher education revenue bonds, hospital revenue bonds, municipal lease revenue bonds, parking revenue bonds, political subdivision general obligation bonds, pre-refunded bonds, school district general obligation bonds, school district revenue bonds, turnpike/toll road revenue bonds, and water and sewer revenue bonds. The fund seeks to maintain an average portfolio maturity of 20 to 30 years. It benchmarks the performance of its portfolio against the Barclays Municipal Bond Index and Lipper CE Other States Municipal Debt Funds Average. Delaware Investments Colorado Insured Municipal Income Fund, Inc. was formed on July 29, 1993 and is domiciled in the United States.

Full VCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VCF vs SCHDVCF vs JEPIVCF vs OVCF vs KOVCF vs MAINVCF vs JNJVCF vs ABBVVCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.